"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
(Generic versions may still be available.)
PROVISC (sodium hyaluronate) Viscoelastic Preparation serves to maintain a deep anterior chamber during anterior segment surgery allowing reduced trauma to the corneal endothelium and surrounding ocular tissues. The viscoelastic properties of PROVISC (sodium hyaluronate) Viscoelastic Preparation help to push back the vitreous face and prevent formation of a flat chamber postoperatively.
PROVISC (sodium hyaluronate) is a sterile, non-pyrogenic, viscoelastic preparation(sodium hyaluronate, 10mg/mL, dissolved in physiological sodium chloride phosphate buffer) supplied in disposable glass syringes delivering 0.55mL or 0.85mL.
Each mL of PROVISC Viscoelastic Preparation contains 10mg sodium hyaluronate; 0.56mg dibasic sodium phosphate, anhydrous; 0.04mg monobasic sodium phosphate; 8.4mg sodium chloride; hydrochloric acid and/or sodium hydroxide to adjust pH and QS water for injection. PROVISC (sodium hyaluronate) syringes are aseptically packaged in blister packs and terminally sterilized.
Store in refrigerator (2° †? 8°C, 36° †? 46°F). Protect from freezing. Protect from light.
Refrigerated PROVISC (sodium hyaluronate) Viscoelastic Preparation should be allowed to attain room temperature prior to use (approximately 20 †? 40 minutes depending on quantity).
Last reviewed on RxList: 2/15/2005
This monograph has been modified to include the generic and brand name in many instances.
Additional Provisc Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.